表紙
市場調査レポート

婦人科系疾患の治療:技術・世界市場

Therapeutics for Women's Health: Technologies and Global Markets

発行 BCC Research 商品コード 84304
出版日 ページ情報 英文 230 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
婦人科系疾患の治療:技術・世界市場 Therapeutics for Women's Health: Technologies and Global Markets
出版日: 2016年05月12日 ページ情報: 英文 230 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界における婦人科系疾患治療の市場額は、2015年におよそ330億米ドルとなりました。この額は今後、4.2%のCAGR (複合年間成長率) で拡大し、2020年には406億米ドル近くに達すると予測されています。

当レポートでは、世界の婦人科系疾患治療市場における動向の分析、疾患タイプ別の分析、医薬品の年間コストの詳細分析、市場成長促進・阻害因子、競合および市場シェアといった市場要因の分析などを提供しています。

第1章 イントロダクション

第2章 サマリー

第3章 婦人科系疾患の概要

  • 疾患の概要と定義
  • 歴史的背景
  • 高齢化と婦人科系疾患
  • 避妊具の新たな利用法
  • 女性と性の健康
  • 不妊と癌

第4章 更年期関連の症状・疾患

  • 概要
  • 病因
  • 疫学・経済的負担
  • 更年期の症状
  • 若年性更年期のリスク因子
  • 診断と治療

第5章 閉経後骨粗しょう症

  • 疾患の概要
  • 疫学・経済的負担
  • 症状・リスク因子
  • 診断・治療
  • 骨粗しょう症のリスクの軽減

第6章 子宮内膜症

  • 疾患の概要
  • 疫学・経済的負担
  • 症状・リスク因子
  • 子宮内膜症の段階
  • 疫学・経済的負担
  • 診断・治療

第7章 多嚢胞性卵巣症候群 (PCOS)

  • 疾患の概要
  • 病因
  • 疫学・経済的負担
  • 症状・リスク因子
  • 診断・治療
  • 多嚢胞性卵巣症候群のリスクの軽減

第8章 乳癌

  • 疾患の概要
  • 病因と病態生理学
  • 症状・リスク因子
  • 乳癌の種類と段階
  • 疫学・経済的負担
  • 診断・治療

第9章 婦人科系疾患治療市場の評価

  • 世界の女性の健康市場
    • 子宮内膜症
    • 更年期
    • 閉経後骨粗しょう症
    • 多嚢胞性卵巣症候群
    • 乳癌
  • 年間の治療費
    • ジェネリック医薬品とブランド医薬品
    • 市場成長促進因子・阻害因子

第10章 競合・市場シェア

第11章 市場戦略

  • M&A

第12章 薬剤パイプライン分析

  • 開発中の薬剤

第13章 規制構造

  • 米国
  • 欧州
  • 日本

第14章 薬価・償還

  • 米国
  • 欧州
  • 日本

第15章 結論:婦人科系疾患治療の展望

  • 市場に影響を及ぼす主な発展
  • 将来の展望

第16章 企業プロファイル

第17章 産業・専門組織

第18章 略語集

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BIO043F

REPORT HIGHLIGHTS

The global market for women's health therapeutics will grow from nearly $33.0 billion in 2015 to nearly $40.6 billion by 2020, with a compound annual growth rate (CAGR) of 4.2% for the period of 2015-2020.

This report provides:

  • An overview of the global market for women's health therapeutics.
  • Analyses of global market trends, with data from 2014, 2015, and projections of CAGRs through 2020.
  • Information on women's health disorder types including infertility, endometriosis, postmenopausal osteoporosis, menopause, and polycystic ovary syndrome (PCOS).
  • Detailed analysis of annual costs as well discussion on branded vs. generic options.
  • Specifics on market factors such as drivers, restraints, and competition.
  • Information on marketed as well as pipeline drugs and therapies.
  • Profiles of major players in the industry.

SCOPE OF THE REPORT

This report is an analytical business tool whose primary purpose is to describe the thorough evaluation of the global market for women's health therapeutics. The format of the study is organized around the following topics:

  • Detailed study around women's diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and polycystic ovary syndrome (PCOS).
  • Disease incidence and prevalence.
  • Regulatory structure.
  • Market characterization, unmet need, market size and segmentation.
  • Market drivers and restraints.
  • Detailed market projections through 2020.
  • Competition and market shares.
  • Pricing and reimbursement.
  • Marketed and pipeline (R&D) products along with description, regulatory status and clinical trials.
  • Observations and conclusions regarding the future of women's health therapeutics market.
  • Profiles of market participants and associations.

ANALYST'S CREDENTIALS

Dr. Ritu Thakur Dangi is the author of this report. She is an independent consultant based in New Delhi, India. She has prior work experience with Panasonic (Healthcare Division) and GlobalData (U.K.-based market research firm). In her previous assignments, she has written many reports on pharmaceutical, medical and biotechnology areas.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY BACKGROUND
  • STUDY GOALS AND OBJECTIVES
  • INTENDED AUDIENCE
  • SCOPE OF THE REPORT
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • EXECUTIVE SUMMARY
  • SUMMARY TABLE: GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS, 2014-2020 ($ MILLIONS)

CHAPTER 3 - OVERVIEW OF WOMEN'S HEALTH DISORDERS

  • DISEASE OVERVIEW AND DEFINITIONS
    • TABLE 1: GLOBAL GENERAL FEMALE POPULATION VS POPULATION SUFFERING FROM A WOMEN'S DISORDER, THROUGH 2020 (MILLIONS)
    • FIGURE 1: DISTRIBUTION OF GLOBAL POPULATION SUFFERING FROM A WOMEN'S DISORDER BY TYPE, 2015 (% OF TOTAL GENERAL FEMALE POPULATION)
  • HISTORICAL BACKGROUND
    • AGING AND WOMEN'S HEALTH DISORDERS
      • FIGURE 2: FEMALE LIKELIHOOD OF BECOMING PREGNANT VERSUS INFERTILITY AS AGE PROGRESSES, 2015 (%)
  • NEW USE FOR CONTRACEPTIVES
  • WOMEN AND SEXUAL HEALTH
    • FEMALE SEXUAL AROUSAL DISORDER
    • FEMALE ORGASMIC DISORDER
    • VAGINISMUS
    • INFERTILITY AND CANCER

CHAPTER 4 - MENOPAUSE-RELATED SYMPTOMS AND DISEASES

  • OVERVIEW
  • ETIOLOGY
  • EPIDEMIOLOGY AND ECONOMIC BURDEN
    • TABLE 2: GLOBAL PREVALENCE OF MENOPAUSE-RELATED CONDITIONS BY REGION, THROUGH 2020 (MILLIONS)
    • FIGURE 3: GLOBAL PREVALENCE OF MENOPAUSE-RELATED CONDITIONS BY REGION, 2014-2020 (MILLIONS)
    • FIGURE 4: GLOBAL POPULATION OF FEMALES SUFFERING FROM MENOPAUSE-RELATED CONDITIONS VS THE GENERAL FEMALE POPULATION, 2014-2020 (MILLIONS)
    • FIGURE 5: GLOBAL DISTRIBUTION OF FEMALES SUFFERING FROM MENOPAUSE-RELATED CONDITIONS BY REGION, 2015 (% OF GENERAL FEMALE POPULATION)
  • SYMPTOMS OF MENOPAUSE
  • RISK FACTORS FOR EARLY ONSET MENOPAUSE
  • DIAGNOSIS AND TREATMENT
    • DIAGNOSIS OF MENOPAUSE
    • TREATMENT OPTIONS
      • TABLE 3: COMMONLY PRESCRIBED DRUGS USED TO TREAT THE SYMPTOMS OF MENOPAUSE
      • Minivelle (Estradiol)
      • FemSeven (Estradiol)
      • Premarin (Conjugated Estrogens)
      • Prempro (Conjugated Estrogens/Medroxyprogesterone Acetate Tablets)
      • Vagifem (Estradiol Vaginal Tablets)
      • Femring (Estradiol Acetate Vaginal Ring)
    • ISSUES ASSOCIATED WITH HORMONE THERAPY
    • REDUCING THE RISK OF EARLY MENOPAUSE

CHAPTER 5 - POSTMENOPAUSAL OSTEOPOROSIS

  • DISEASE OVERVIEW
  • HUMAN BONE STRUCTURE
    • EPIDEMIOLOGY AND ECONOMIC BURDEN
      • TABLE 4: GLOBAL PREVALENCE OF POSTMENOPAUSAL OSTEOPOROSIS BY REGION, THROUGH 2020 (MILLIONS)
      • FIGURE 6: GLOBAL PREVALENCE OF POSTMENOPAUSAL OSTEOPOROSIS BY REGION, 2014-2020 (MILLIONS)
      • FIGURE 7: GLOBAL POPULATION OF FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS VS THE OVERALL FEMALE POPULATION, 2014-2020 (MILLIONS)
      • FIGURE 8: GLOBAL DISTRIBUTION OF FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS BY GEOGRAPHIC REGION, 2015 (% OF FEMALE POPULATION)
  • DISEASE SYMPTOMS AND RISK FACTORS
    • DISEASE SYMPTOMS
      • Fractures
      • Spinal Deformities
      • Pain
    • RISK FACTORS
  • DIAGNOSIS AND TREATMENT
    • DIAGNOSIS OF POSTMENOPAUSAL OSTEOPOROSIS
    • TREATMENT OPTIONS FOR POSTMENOPAUSAL OSTEOPOROSIS
      • Bisphosphonates
      • Hormone Therapy
      • Selective Estrogen Receptor Modulators (SERMs)
      • Calcitonin
      • Parathyroid Hormone
        • TABLE 5: COMMONLY PRESCRIBED DRUGS USED TO TREAT POSTMENOPAUSAL OSTEOPOROSIS
      • Caltrate (Calcium Carbonate)
      • Edirol (Eldecalcitol)
      • Pralia (Denosumab)
      • Protelos (Strontium Ranelate)
      • Miacalcin (Calcitonin Salmon)
      • Fosamax (Alendronate Sodium)
      • Actonel (Risedronate Sodium)
      • Evista (Raloxifene Hydrochloride)
      • Boniva (Ibandronate Sodium)
      • Forteo (Teriparatide (rDNA Origin)) Injection
      • Reclast (Zoledronate)
      • Calcitonin (Calcimar, Miacalcin)
      • Forteo (Teriparatide)
      • Aprela (Bazedoxifene/Conjugated Estrogen)
      • Viviant (Bazedoxifene)
    • REDUCING THE RISK OF OSTEOPOROSIS

CHAPTER 6 - ENDOMETRIOSIS

  • DISEASE OVERVIEW
  • ETIOLOGY AND PATHOPHYSIOLOGY
  • DISEASE SYMPTOMS AND RISK FACTORS
    • PELVIC PAIN
    • DIFFICULTY BECOMING PREGNANT
    • ENDOMETRIOMAS
    • RISK FACTORS
      • Genetic Factors
      • Delayed Pregnancy
      • Age
      • Dietary Factors
    • STAGES OF ENDOMETRIOSIS
    • EPIDEMIOLOGY AND ECONOMIC BURDEN
      • TABLE 6: PREVALENCE OF ENDOMETRIOSIS BY REGION, THROUGH 2020 (MILLIONS)
      • FIGURE 9: PREVALENCE OF ENDOMETRIOSIS BY REGION, 2014-2020 (MILLIONS)
      • FIGURE 10: GLOBAL ENDOMETRIOSIS POPULATION VS OVERALL FEMALE POPULATION, 2014-2020 (MILLIONS)
      • FIGURE 11: GLOBAL DISTRIBUTION OF ENDOMETRIOSIS POPULATION BY REGION, 2015 (% OF FEMALE POPULATION)
  • DIAGNOSIS AND TREATMENT
    • DIAGNOSIS OF ENDOMETRIOSIS
      • Pelvic Exam
      • Laparoscopy
      • Other Diagnostic Procedures
    • TREATMENT OPTIONS FOR ENDOMETRIOSIS
      • Pharmacological Treatment
        • NSAIDs
        • Hormonal Birth Control Treatments
        • Progestins
        • Gonadotropin Releasing Hormone Agonists
          • TABLE 7: DRUGS COMMONLY USED TO TREAT ENDOMETRIOSIS
        • Zoladex
        • Visanne (Dienogest)
        • Lupron Depot (Leuprolide Acetate)
        • Synarel (Nafarelin Acetate)
        • Danazol
        • Visanne
      • Surgery
    • LOWERING THE RISK OF ENDOMETRIOSIS

CHAPTER 7 - POLYCYSTIC OVARY SYNDROME

  • DISEASE OVERVIEW
  • ETIOLOGY
  • EPIDEMIOLOGY AND ECONOMIC BURDEN
    • TABLE 8: PREVALENCE OF POLYCYSTIC OVARY SYNDROME BY REGION, THROUGH 2020 (MILLIONS)
    • FIGURE 12: PREVALENCE OF POLYCYSTIC OVARY SYNDROME BY REGION, 2014-2020 (MILLIONS)
    • FIGURE 13: GLOBAL POLYCYSTIC OVARY SYNDROME DISEASE POPULATION VS FEMALE POPULATION, 2014-2020 (MILLIONS)
    • FIGURE 14: GLOBAL DISTRIBUTION OF POLYCYSTIC OVARY SYNDROME POPULATION BY REGION, 2015 (% OF FEMALE POPULATION)
  • DISEASE SYMPTOMS AND RISK FACTORS
  • DIAGNOSIS AND TREATMENT
    • DIAGNOSIS OF POLYCYSTIC OVARY SYNDROME
      • Medical History and Physical Examination
      • Pelvic Examination
      • Laboratory Testing
      • Imaging Tests
    • TREATMENT OPTIONS FOR POLYCYSTIC OVARY SYNDROME
      • TABLE 9: COMMONLY PRESCRIBED GENERIC DRUGS FOR THE TREATMENT OF POLYCYSTIC OVARY SYNDROME
      • Medications
        • Clomid (Clomiphene)
        • Vaniqa (Eflornithine)
        • Glucophage (Metformin)
        • Actos (Pioglitazone) and Avandia (Rosiglitazone)
        • Aldactone (Spironolactone)
        • Precose (Acarbose)
        • Apri (Desogestrel/Ethinyl Estradiol)
        • Propecia (Finasteride)
        • Eulexin (Flutamide)
        • Femara (Letrozole)
    • REDUCING THE RISK OF PCOS

CHAPTER 8 - BREAST CANCER

  • DISEASE OVERVIEW
  • ETIOLOGY AND PATHOPHYSIOLOGY
  • DISEASE SYMPTOMS AND RISK FACTORS
    • SYMPTOMS
    • RISK FACTORS
  • TYPES AND STAGES OF BREAST CANCER
    • TABLE 10: TNM CLASSIFICATIONS OF BREAST CANCERS
    • TABLE 11: FIVE-YEAR SURVIVAL RATE BASED ON STAGE OF BREAST CANCER FOR WOMEN IN THE U.S, 2015 (%)
  • EPIDEMIOLOGY AND ECONOMIC BURDEN
    • TABLE 12: PREVALENCE OF BREAST CANCER BY REGION, THROUGH 2020 (MILLIONS)
    • FIGURE 15: PREVALENCE OF BREAST CANCER BY REGION, 2014-2020 (MILLIONS)
    • FIGURE 16: GLOBAL BREAST CANCER POPULATION VS OVERALL FEMALE POPULATION, 2014-2020 (MILLIONS)
    • FIGURE 17: GLOBAL DISTRIBUTION OF BREAST CANCER POPULATION BY REGION, 2015 (% OF FEMALE POPULATION)
  • DIAGNOSIS AND TREATMENT
    • DIAGNOSIS OF BREAST CANCER
    • TREATMENT OPTIONS FOR BREAST CANCER
      • TABLE 13: TYPES OF HORMONE THERAPY FOR BREAST CANCER
      • Cancer Treatment: Local or Systemic
        • TABLE 14: DRUGS COMMONLY USED TO TREAT BREAST CANCER
      • Medications
        • Alkeran (Melphalan)
        • Taxol (Paclitaxel)
        • Methotrexate Sodium
        • Herceptin (Trastuzumab)
        • Ellence (Epirubicin Hydrochloride)
        • Aromasin (Exemestane)
        • Adrucil (Fluorouracil)
        • Femara (Letrozole)
        • Velban (Vinblastine)
        • Gemzar
        • Abraxane (Paclitaxel [Albumin-bound])
        • Arimidex (Anastrozole)
        • Faslodex (Fulvestrant)
        • Fareston
        • Xeloda (Capecitabine)
        • Zoladex (Goserelin Acetate)
        • Ixempra (Ixabepilone)
        • Tykerb (Lapatinib Ditosylate)
        • Abraxane (Paclitaxel [Albumin-bound])
        • Perjeta (Pertuzumab)
        • Ibrance (Palbociclib)
        • Kadcyla (Ado-trastuzumab Emtansine)
        • Halaven (Eribulin Mesylate)
        • Afinitor (Everolimus)
        • Avastin (Bevacizumab)
        • Leuplin (Leuprolide Acetate)
        • Taxotere (Docetaxel)
        • Prognosis After Treatment
        • Breast Cancer Treatment Guidelines
        • Prevention

CHAPTER 9 - WOMEN'S HEALTH DISORDER THERAPEUTICS MARKET ASSESSMENT

  • GLOBAL WOMEN'S HEALTH MARKET
    • FIGURE 18: GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET BY REGION, 2014-2020 ($ MILLIONS)
    • FIGURE 19: GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET BY DISORDER TYPE, 2014-2020 ($ MILLIONS)
    • FIGURE 20: GLOBAL MARKET SHARES OF WOMEN'S HEALTH THERAPEUTICS MARKET BY DISORDER TYPE, 2015 (%)
    • FIGURE 21: AVERAGE ANNUAL COST OF THERAPY FOR WOMEN'S HEALTH DISORDERS, 2014-2020 ($)
  • ENDOMETRIOSIS
    • FIGURE 22: GLOBAL ENDOMETRIOSIS THERAPEUTICS MARKET BY REGION, 2014-2020 ($ MILLIONS)
  • MENOPAUSE
    • FIGURE 23: GLOBAL MARKET FOR THERAPEUTICS TO TREAT MENOPAUSE-RELATED CONDITIONS BY REGION, 2014-2020 ($ MILLIONS)
  • POSTMENOPAUSAL OSTEOPOROSIS
    • FIGURE 24: GLOBAL POSTMENOPAUSAL OSTEOPOROSIS THERAPEUTICS MARKET BY REGION, 2014-2020 ($ MILLIONS)
  • POLYCYSTIC OVARY SYNDROME
    • FIGURE 25: GLOBAL MARKET FOR POLYCYSTIC OVARY SYNDROME THERAPEUTICS BY REGION, 2014-2020 ($ MILLIONS)
  • BREAST CANCER
    • FIGURE 26: GLOBAL BREAST CANCER THERAPEUTICS MARKET BY REGION, 2014-2020 ($ MILLIONS)
  • ANNUAL COST OF THERAPY
    • FIGURE 27: GLOBAL AVERAGE ANNUAL COST OF THERAPY BY DISORDER, 2014-2020 ($)
  • GENERICS VERSUS BRANDED
    • FIGURE 28: GLOBAL SHARES OF WOMEN'S HEALTH THERAPEUTICS MARKET: BRANDED VS. GENERIC, 2015 (%)
  • MARKET GROWTH DRIVERS AND RESTRAINTS
    • Growth Drivers for Menopause-Related Conditions
      • Aging Female Population
    • Growth Restraints for Menopause
      • Low Rate of Prescriptions for Hormone Therapy
      • Availability of Alternative Treatment Options
      • Lack of Safe and Efficacious Drug
    • Growth Drivers for Endometriosis
      • Increasing Awareness
    • Growth Restraints for Endometriosis
      • Poor Diagnosis
      • Absence of Non-hormonal Therapy
    • Growth Drivers for Postmenopausal Osteoporosis
      • Increasing Disease Population
      • Sedentary Lifestyle
    • Growth Restraints for Postmenopausal Osteoporosis
      • Poor Diagnosis
    • Growth Drivers for PCOS
      • Growing Treated Population
    • Growth Restraints for PCOS
      • Unavailability of Novel Drugs
    • Growth Drivers for Breast Cancer
      • Increasing Prevalence of Breast Cancer
      • Rising Government Involvement
      • Increasing Funding
      • Ethical Acceptance
      • DNA Vaccines
    • Growth Restraints for Breast Cancer
      • Lack of Awareness
      • High Cost

CHAPTER 10 - COMPETITION AND MARKET SHARES

  • TABLE 15: LEADING COMPANIES IN THE GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS, 2015 ($ MILLIONS/%)
  • FIGURE 29: GLOBAL MARKET SHARES OF LEADING COMPANIES IN WOMEN'S HEALTH THERAPEUTICS INDUSTRY, 2015 (%)

CHAPTER 11 - MARKET STRATEGY

  • TABLE 16: KEY MERGERS/ACQUISITIONS WITHIN THE WOMEN'S HEALTH MARKET, 2009-JANUARY 2016
  • MERGERS AND ACQUISITIONS
    • TRILLIUM THERAPEUTICS' ACQUISITION OF FLUORINOV PHARMA
    • SHIRE'S ACQUISITION OF DYAX
    • ASTRAZENECA SELLS PCOS CANDIDATE RIGHTS TO MILLENDO THERAPEUTICS
    • PFIZER'S ACQUISITION OF HOSPIRA
    • MEDIVATION'S ACQUISITION OF OF ALL WORLDWIDE RIGHTS TO TALAZOPARIB (BMN 673), A POTENT PARP INHIBITOR, FROM BIOMARIN
    • SHIRE'S ACQUISITION OF NPS PHARMACEUTICALS
    • OPKO HEALTH'S ACQUISITION OF EIRGEN PHARMA
    • ABBVIE'S ACQUISITION OF PHARMACYCLICS
    • ACTAVIS' ACQUISITION OF ALLERGAN
    • NOVARTIS' ACQUISITION OF GSK'S ONCOLOGY DIVISION
    • ENDO INTERNATIONAL'S ACQUISITION OF PAR PHARMACEUTICAL
    • VALEANT'S ACQUISITION OF DENDREON
    • SUN PHARMACEUTICALS' ACQUISITION OF RANBAXY
    • ABBOTT'S ACQUISITION OF VEROPHARM
    • ROCHE'S ACQUISITION OF SERAGON PHARMACEUTICALS
    • BAYER'S ACQUISITION OF ALGETA
    • ENDO INTERNATIONAL'S ACQUISITION OF PALADIN LABS
    • PRESCIENT THERAPEUTICS' ACQUISITION OF AKTIVATE THERAPEUTICS AND PATHWAY ONCOLOGY
    • ACTAVIS' ACQUISITION OF WARNER CHILCOTT
    • AMGEN'S ACQUISITION OF MUSTAFA NEVZAT (MN) PHARMACEUTICALS
    • VALEANT PHARMACEUTICALS' ACQUISITION OF INOVA
    • TAKEDA'S ACQUISITION OF NYCOMED
    • TEVA PHARMACEUTICAL'S ACQUISITION OF THERAMEX
    • THERAPEUTICSMD'S ACQUISITION OF VITAMEDMD
    • SANOFI-AVENTIS' ACQUISITION OF BMP SUNSTONE
    • ABBOTT'S ACQUISITION OF SOLVAY PHARMACEUTICALS
    • FERRING PHARMACEUTICALS' ACQUIRED GLOBAL RIGHTS TO LYSTEDA FROM XANODYNE PHARMACEUTICALS
    • BIOSANTE ACQUIRED ELESTRIN ROYALTY FROM AZUR PHARMA
    • TEVA-KOWA PHARMA ACQUIRED MAJORITY STAKE IN TAISHO PHARMACEUTICAL
    • SCIELE PHARMA'S ACQUISITION OF ADDRENEX PHARMACEUTICALS
    • WARNER CHILCOTT'S ACQUISITION OF PROCTER & GAMBLE'S PRESCRIPTION DRUG BUSINESS
    • BIOSANTE PHARMACEUTICALS MERGES WITH CELL GENESYS
    • HISAMITSU PHARMACEUTICAL'S ACQUISITION OF NOVEN PHARMACEUTICALS
    • PFIZER'S ACQUISITION OF WYETH
    • PAR PHARMACEUTICALS' ACQUISITION OF MDRNA'S CALCITONIN ASSETS AND MANUFACTURING FACILITY

CHAPTER 12 - DRUG PIPELINE ANALYSIS

  • TABLE 17: PIPELINE DRUGS IN WOMEN'S HEALTH
  • DRUGS UNDER DEVELOPMENT
    • PB272 (NERATINIB)
      • Description
      • Safety/Efficacy
      • Clinical Trials
    • ABP 215 (BEVACIZUMAB)
      • Description
      • Clinical Trials
    • AD-RTS-IL-12
      • Description
      • Clinical Trials
    • ABEMACICLIB (LY2835219)
      • Description
      • Clinical Trials
    • ATEZOLIZUMAB
      • Description
      • Clinical Trials
    • BUPARLISIB (BKM120)
      • Description
      • Clinical Trials
    • ALPELISIB (BYL719)
      • Description
      • Clinical Trials
    • CDX-011 (GLEMBATUMUMAB VEDOTIN)
      • Description
      • Clinical Trials
    • ENTINOSTAT
      • Description
      • Clinical Trials
    • LEE011 (RIBOCICLIB)
      • Description
      • Clinical Trials
    • LYNPARZA (OLAPARIB)
      • Description
      • Clinical Trials
    • TRASTUZUMAB
    • VELIPARIB (ABT-888)
      • Description
      • Clinical Trials
    • TASELISIB
    • TALAZOPARIB (BMN 673)
      • Description
      • Clinical Trials
    • NK105 (PACLITAXEL)
    • NIRAPARIB
      • Description
      • Clinical Trials
    • JDS-CR-004 (ORAL, PCOS)
      • Description
      • Clinical Trials
    • DIAMEL
      • Description
      • Clinical Trials
    • DLBS-3233; INLACIN
    • MLE4901
      • Description
      • Clinical Trials
    • BAYER- SPRM (BAY 1002670) VILAPRISAN
      • Description
      • Clinical Trials
    • INTRAVAGINAL RING (BAY 98-7196)
    • OBE2109
      • Description
      • Clinical Trials
    • ABALOPARATIDE-SC
      • Description
      • Clinical Trials
    • RAD1901
      • Description
      • Clinical Trials
    • BPS-804
      • Description
      • Clinical Trials
    • BA058/ITM-058 (ABALOPARATIDE)
    • CAPSITONIN (CALCITONIN SALMON) AND CAPTHYMONE (PARATHYROID HORMONE)
    • FABLYN (LASOFOXIFENE)
    • PREOB (AUTOLOGOUS OSTEOBLAST)
      • Description
      • Clinical Trials
    • SALUBRIN HF
    • TBRIA (CALCITONIN-SALMON [RDNA ORIGIN])
      • Description
      • Clinical Trials
    • TX 12-002-HR (PROGESTERONE)
      • Description
      • Clinical Trials
    • TAK-385 (RELUGOLIX)
      • Description
      • Safety/Efficacy
      • Clinical Trials
    • ELAGOLIX
      • Description
      • Safety/Efficacy
      • Clinical Trials
    • ASP1707
      • Description
      • Clinical Trials
    • PROELLEX (TELAPRISTONE ACETATE) (6 MG AND 12 MG, LOW DOSE ORAL)
      • Description
      • Safety/Efficacy
      • Low Dose Oral Study
      • Vaginal Administration
    • PGL2001 (PGL2)
      • Description
      • Safety/Efficacy
      • Clinical Trials
    • PGL5001 (PGL5) (BENTAMAPIMOD/PROOF OF CONCEPT)
      • Description
      • Clinical Trials
    • KLH-2109
      • Description
      • Clinical Trials
    • AUS-131 (S-EQUOL)
      • Description
      • Safety/Efficacy
      • Clinical Trials
    • MPI-676 AND MPI-674 (FEMATHINA)
      • Description
      • Clinical Trials
    • 17HSD1 (17-BETA-HYDROXYSTEROID DEHYDROGENASE 1)
      • Description
      • Safety/Efficacy
      • Clinical Trials
    • FEMITRA (ACOLBIFENE + DHEA (ORAL) + GNRH AGONIST) (SUBCUTANEOUS)
      • Description
    • BAY 1026153
      • Description
    • MK-0822 (ODANACATIB)
      • Description
      • Safety and Efficacy
      • Clinical Trials
    • MENERBA
      • Description
      • Safety/Efficacy
      • Clinical Trials
    • SEALA
      • Description
      • Clinical Trials
    • BA058-SC (ABALOPARATIDE)
      • Description
      • Safety/Efficacy
      • Clinical Trials
    • BA058-TD (TRANSDERMAL DELIVERY)
      • Description
      • Safety/Efficacy
      • Clinical Trials
    • RAD1901
      • Description
      • Safety/Efficacy
      • Clinical Trials
    • ZP-PTH (TERIPARATIDE)
      • Description
      • Safety/Efficacy
      • Clinical Trials
    • RECOMBINANT ORAL SALMON CALCITONIN
      • Description
      • Safety/Efficacy
      • Clinical Trials
    • ESN364
      • Description
      • Safety/Efficacy
      • Clinical Trials
    • VAGINORM
      • Description
      • Clinical Trials
    • AZD4901
      • Description
      • Clinical Trials
    • ESTRADIOL + TESTOSTERONE GEL
      • Description
    • AMG 785/CDP7851 (ROMOSOZUMAB)
      • Description
      • Safety/Efficacy
      • Clinical Trials
    • TX 12-001HR (17B ESTRADIOL + PROGESTERONE)
      • Description
      • Clinical Trials

CHAPTER 13 - REGULATORY STRUCTURE

  • UNITED STATES
  • EUROPE
    • REGULATORY PROCEDURES
      • National Authorization Procedure
      • Centralized Procedure
      • Decentralized Procedure
      • Mutual Recognition Procedure
  • JAPAN

CHAPTER 14 - PRICING AND REIMBURSEMENT

  • UNITED STATES
  • EUROPE
  • JAPAN

CHAPTER 15 - CONCLUSIONS-OUTLOOK FOR WOMEN'S HEALTH THERAPEUTICS

  • MAJOR DEVELOPMENTS TO INFLUENCE MARKET
    • THERAPEUTIC DEVELOPMENTS
    • DEMOGRAPHIC AND ECONOMIC TRENDS
      • Increasing Aging Population
        • TABLE 18: ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2005-2020 (YEARS)
        • FIGURE 30: ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2005-2020 (YEARS)
        • TABLE 19: PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)
        • FIGURE 31: PROJECTED GLOBAL FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)
        • TABLE 20: PROJECTED U.S. FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)
        • FIGURE 32: PROJECTED U.S. FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)
        • TABLE 21: PROJECTED EUROPEAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)
        • FIGURE 33: PROJECTED EUROPEAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)
        • TABLE 22: PROJECTED JAPAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)
        • FIGURE 34: PROJECTED JAPAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)
      • Income Growth in Developing Markets
        • TABLE 23: PROJECTED TRENDS IN PER CAPITA REAL GDP GROWTH BY REGION, 2015-2020 (ANNUAL AVERAGE PERCENTAGE CHANGE)
    • TRENDS IN REIMBURSEMENT
  • FUTURE OUTLOOK

CHAPTER 16 - COMPANY PROFILES

  • ABBVIE
  • ALLERGAN
  • AMGEN
  • ASAHI KASAI
  • ASTELLAS PHARMA INC.
  • ASTRAZANECA
  • BAYER
  • BIONOVO
  • CELGENE
  • CHUGAI PHARMACEUTICALS
  • DEPOMED INC.
  • EISAI
  • ELI LILLY
  • ENDOCEUTICS
  • FORENDO PHARMA OY
  • GLAXOSMITHKLINE
  • IPSEN SA
  • LES LABORATORIES SERVIER SAS
  • MERCK
  • MOCHIDA PHARMA CO. LTD.
  • MEDITRINA PHARMACEUTICALS INC.
  • NEUROCRINE BIOSCIENCES INC.
  • NOVARTIS AG
  • NOVO NORDISK A/S
  • NOVOGYNE PHARMACEUTICALS
  • OASMIA PHARMACEUTICAL
  • ORION PHARMA LTD.
  • OTSUKA HOLDINGS
  • PALADIN LABS INC.
  • PFIZER INC.
  • PREGLEM SA
  • PUMA BIOTECHNOLOGY
  • ROCHE
  • RADIUS HEALTH INC.
  • REPROS THERAPEUTICS INC.
  • SANOFI
  • TAKEDA PHARMACEUTICAL
  • TARSA THERAPEUTICS INC.
  • TEVA PHARMACEUTICAL INDUSTRIES
  • THERAPEUTICSMD
  • TSUMURA & CO.
  • WARNER CHILCOTT CORP. (SUBSIDIARY OF ACTAVIS)
  • ZIOPHARM ONCOLOGY
  • ZOSANO PHARMA INC.

CHAPTER 17 - INDUSTRY AND PROFESSIONAL ORGANIZATIONS

  • AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR)
  • AMERICAN CANCER SOCIETY
  • AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE (ASRM)
  • AMERICAN SOCIETY OF BREAST SURGEONS
  • AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)
  • ANDROGEN EXCESS AND PCOS SOCIETY
  • ASIA-PACIFIC MENOPAUSE FEDERATION
  • AVON BREAST CANCER CRUSADE
  • BREASTCANCER.ORG
  • ENDOMETRIOSIS ASSOCIATION
  • ENDOMETRIOSIS FOUNDATION OF AMERICA (EFA)
  • ENDOMETRIOSIS.ORG
  • ENDOMETRIOSIS RESEARCH CENTRE (ERC)
  • ENDOMETRIOSIS U.K.
  • EUROPEAN CANCER OBSERVATORY
  • EUROPEAN ENDOMETRIOSIS LEAGUE (EEL)
  • EUROPEAN MENOPAUSE AND ANDROPAUSE SOCIETY (EMAS)
  • EUROPEAN SOCIETY OF HUMAN REPRODUCTION AND EMBRYOLOGY (ESHRE)
  • FOOD AND DRUG ADMINISTRATION (FDA)
  • GLOBAL CANCER FOUNDATION
  • HORMONE FOUNDATION
  • INTERNATIONAL AGENCY FOR RESEARCH ON CANCER
  • INTERNATIONAL FEDERATION OF PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS (IFPMA)
  • INTERNATIONAL MENOPAUSE SOCIETY (IMS)
  • INTERNATIONAL OSTEOPOROSIS FOUNDATION (IOF)
  • JAPAN ENDOMETRIOSIS ASSOCIATION (JEMA)
  • JAPAN SOCIETY FOR MENOPAUSE AND WOMEN'S HEALTH
  • JAPANESE BREAST CANCER SOCIETY
  • NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION (NCBI)
  • NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN)
  • NATIONAL INSTITUTE ON AGING (NIA)
  • NORTH AMERICAN MENOPAUSE SOCIETY (NAMS)
  • NATIONAL OSTEOPOROSIS FOUNDATION (NOF)
  • NATIONAL WOMEN'S HEALTH INFORMATION CENTER (NWHIC)
  • PCOSUPPORT
  • WORLD CANCER RESEARCH FUND INTERNATIONAL
  • WORLD ENDOMETRIOSIS RESEARCH FOUNDATION (WERF)
  • WORLDWIDE CANCER RESEARCH

CHAPTER 18 - ABBREVIATIONS

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
    • TABLE 1: GLOBAL GENERAL FEMALE POPULATION VS POPULATION SUFFERING FROM A WOMEN'S DISORDER, THROUGH 2020 (MILLIONS)
    • TABLE 2: GLOBAL PREVALENCE OF MENOPAUSE-RELATED CONDITIONS BY REGION, THROUGH 2020 (MILLIONS)
    • TABLE 3: COMMONLY PRESCRIBED DRUGS USED TO TREAT THE SYMPTOMS OF MENOPAUSE
    • TABLE 4: GLOBAL PREVALENCE OF POSTMENOPAUSAL OSTEOPOROSIS BY REGION, THROUGH 2020 (MILLIONS)
    • TABLE 5: COMMONLY PRESCRIBED DRUGS USED TO TREAT POSTMENOPAUSAL OSTEOPOROSIS
    • TABLE 6: PREVALENCE OF ENDOMETRIOSIS BY REGION, THROUGH 2020 (MILLIONS)
    • TABLE 7: DRUGS COMMONLY USED TO TREAT ENDOMETRIOSIS
    • TABLE 8: PREVALENCE OF POLYCYSTIC OVARY SYNDROME BY REGION, THROUGH 2020 (MILLIONS)
    • TABLE 9: COMMONLY PRESCRIBED GENERIC DRUGS FOR THE TREATMENT OF POLYCYSTIC OVARY SYNDROME
    • TABLE 10: TNM CLASSIFICATIONS OF BREAST CANCERS
    • TABLE 11: FIVE-YEAR SURVIVAL RATE BASED ON STAGE OF BREAST CANCER FOR WOMEN IN THE U.S, 2015 (%)
    • TABLE 12: PREVALENCE OF BREAST CANCER BY REGION, THROUGH 2020 (MILLIONS)
    • TABLE 13: TYPES OF HORMONE THERAPY FOR BREAST CANCER
    • TABLE 14: DRUGS COMMONLY USED TO TREAT BREAST CANCER
    • TABLE 15: LEADING COMPANIES IN THE GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS, 2015 ($ MILLIONS/%)
    • TABLE 16: KEY MERGERS/ACQUISITIONS WITHIN THE WOMEN'S HEALTH MARKET, 2009-JANUARY 2016
    • TABLE 17: PIPELINE DRUGS IN WOMEN'S HEALTH
    • TABLE 18: ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2005-2020 (YEARS)
    • TABLE 19: PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)
    • TABLE 20: PROJECTED U.S. FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)
    • TABLE 21: PROJECTED EUROPEAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)
    • TABLE 22: PROJECTED JAPAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)
    • TABLE 23: PROJECTED TRENDS IN PER CAPITA REAL GDP GROWTH BY REGION, 2015-2020 (ANNUAL AVERAGE PERCENTAGE CHANGE)

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS, 2014-2020 ($ MILLIONS)
    • FIGURE 1: DISTRIBUTION OF GLOBAL POPULATION SUFFERING FROM A WOMEN'S DISORDER BY TYPE, 2015 (% OF TOTAL GENERAL FEMALE POPULATION)
    • FIGURE 2: FEMALE LIKELIHOOD OF BECOMING PREGNANT VERSUS INFERTILITY AS AGE PROGRESSES, 2015 (%)
    • FIGURE 3: GLOBAL PREVALENCE OF MENOPAUSE-RELATED CONDITIONS BY REGION, 2014-2020 (MILLIONS)
    • FIGURE 4: GLOBAL POPULATION OF FEMALES SUFFERING FROM MENOPAUSE-RELATED CONDITIONS VS THE GENERAL FEMALE POPULATION, 2014-2020 (MILLIONS)
    • FIGURE 5: GLOBAL DISTRIBUTION OF FEMALES SUFFERING FROM MENOPAUSE-RELATED CONDITIONS BY REGION, 2015 (% OF GENERAL FEMALE POPULATION)
    • FIGURE 6: GLOBAL PREVALENCE OF POSTMENOPAUSAL OSTEOPOROSIS BY REGION, 2014-2020 (MILLIONS)
    • FIGURE 7: GLOBAL POPULATION OF FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS VS THE OVERALL FEMALE POPULATION, 2014-2020 (MILLIONS)
    • FIGURE 8: GLOBAL DISTRIBUTION OF FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS BY GEOGRAPHIC REGION, 2015 (% OF FEMALE POPULATION)
    • FIGURE 9: PREVALENCE OF ENDOMETRIOSIS BY REGION, 2014-2020 (MILLIONS)
    • FIGURE 10: GLOBAL ENDOMETRIOSIS POPULATION VS OVERALL FEMALE POPULATION, 2014-2020 (MILLIONS)
    • FIGURE 11: GLOBAL DISTRIBUTION OF ENDOMETRIOSIS POPULATION BY REGION, 2015 (% OF FEMALE POPULATION)
    • FIGURE 12: PREVALENCE OF POLYCYSTIC OVARY SYNDROME BY REGION, 2014-2020 (MILLIONS)
    • FIGURE 13: GLOBAL POLYCYSTIC OVARY SYNDROME DISEASE POPULATION VS FEMALE POPULATION, 2014-2020 (MILLIONS)
    • FIGURE 14: GLOBAL DISTRIBUTION OF POLYCYSTIC OVARY SYNDROME POPULATION BY REGION, 2015 (% OF FEMALE POPULATION)
    • FIGURE 15: PREVALENCE OF BREAST CANCER BY REGION, 2014-2020 (MILLIONS)
    • FIGURE 16: GLOBAL BREAST CANCER POPULATION VS OVERALL FEMALE POPULATION, 2014-2020 (MILLIONS)
    • FIGURE 17: GLOBAL DISTRIBUTION OF BREAST CANCER POPULATION BY REGION, 2015 (% OF FEMALE POPULATION)
    • FIGURE 18: GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET BY REGION, 2014-2020 ($ MILLIONS)
    • FIGURE 19: GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET BY DISORDER TYPE, 2014-2020 ($ MILLIONS)
    • FIGURE 20: GLOBAL MARKET SHARES OF WOMEN'S HEALTH THERAPEUTICS MARKET BY DISORDER TYPE, 2015 (%)
    • FIGURE 21: AVERAGE ANNUAL COST OF THERAPY FOR WOMEN'S HEALTH DISORDERS, 2014-2020 ($)
    • FIGURE 22: GLOBAL ENDOMETRIOSIS THERAPEUTICS MARKET BY REGION, 2014-2020 ($ MILLIONS)
    • FIGURE 23: GLOBAL MARKET FOR THERAPEUTICS TO TREAT MENOPAUSE-RELATED CONDITIONS BY REGION, 2014-2020 ($ MILLIONS)
    • FIGURE 24: GLOBAL POSTMENOPAUSAL OSTEOPOROSIS THERAPEUTICS MARKET BY REGION, 2014-2020 ($ MILLIONS)
    • FIGURE 25: GLOBAL MARKET FOR POLYCYSTIC OVARY SYNDROME THERAPEUTICS BY REGION, 2014-2020 ($ MILLIONS)
    • FIGURE 26: GLOBAL BREAST CANCER THERAPEUTICS MARKET BY REGION, 2014-2020 ($ MILLIONS)
    • FIGURE 27: GLOBAL AVERAGE ANNUAL COST OF THERAPY BY DISORDER, 2014-2020 ($)
    • FIGURE 28: GLOBAL SHARES OF WOMEN'S HEALTH THERAPEUTICS MARKET: BRANDED VS. GENERIC, 2015 (%)
    • FIGURE 29: GLOBAL MARKET SHARES OF LEADING COMPANIES IN WOMEN'S HEALTH THERAPEUTICS INDUSTRY, 2015 (%)
    • FIGURE 30: ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2005-2020 (YEARS)
    • FIGURE 31: PROJECTED GLOBAL FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)
    • FIGURE 32: PROJECTED U.S. FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)
    • FIGURE 33: PROJECTED EUROPEAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)
    • FIGURE 34: PROJECTED JAPAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)
Back to Top